Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction

Mutagenesis

Volumn 26, Issue 5, 2011, Pages 619-628

  Wang, Yiying ^a   Meng, Fanxue ^a   Arlt, Volker M ^b   Mei, Nan ^a   Chen, Tao ^a   Parsons, Barbara L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; BIOLOGICAL MARKER;

ALLELE; ALLELE SPECIFIC BLOCKER POLYMERASE CHAIN REACTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; KIDNEY; LIVER; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT;

ALLELES; ANIMALS; ARISTOLOCHIC ACIDS; CELL TRANSFORMATION, NEOPLASTIC; CODON; DNA ADDUCTS; GENES, RAS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RATS; RATS, TRANSGENIC;

MUS; RATTUS; RODENTIA;

EID: 80052341469     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger023     Document Type: Article

References (62)

1. Schmeiser, H. H., Stiborova, M. and Arlt, V. M. (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr. Opin. Drug Discov. Devel., 12, 141-148.
2. Arlt, V. M., Stiborova, M. and Schmeiser, H. H. (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis, 17, 265-277.
3. Vanherweghem, J. L., Depierreux, M., Tielemans, C. et al. (1993) Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet, 341, 387-391.
4. Cosyns, J. P., Jadoul, M., Squifflet, J. P., Wese, F. X. and van Ypersele de Strihou, C. (1999) Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis., 33, 1011-1017.
5. Nortier, J. L., Martinez, M. C., Schmeiser, H. H. et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med., 342, 1686-1692.
6. Debelle, F. D., Vanherweghem, J. L. and Nortier, J. L. (2008) Aristolochic acid nephropathy: A worldwide problem. Kidney Int., 74, 158-169.
7. Arlt, V. M., Stiborova, M., vom Brocke, J., Simoes, M. L., Lord, G. M., Nortier, J. L., Hollstein, M., Phillips, D. H. and Schmeiser, H. H. (2007) Aristolochic acid mutagenesis: Molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis, 28, 2253-2261.
8. Grollman, A. P., Shibutani, S., Moriya, M. et al. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. USA, 104, 12129-12134.
9. Mengs, U. (1983) On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch. Toxicol., 52, 209-220.
10. Mengs, U. (1988) Tumour induction in mice following exposure to aristolochic acid. Arch. Toxicol., 61, 504-505.
11. Mengs, U., Lang, W. and Poch, J. A. (1982) The carcinogenic action of aristolochic acid in rats. Arch. Toxicol., 51, 107-119.
12. Debelle, F. D., Nortier, J. L., De Prez, E. G., Garbar, C. H., Vienne, A. R., Salmon, I. J., Deschodt-Lanckman, M. M. and Vanherweghem, J. L. (2002) Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol., 13, 431-436.
13. Cosyns, J. P., Goebbels, R. M., Liberton, V., Schmeiser, H. H., Bieler, C. A. and Bernard, A. M. (1998) Chinese herbs nephropathyassociated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch. Toxicol., 72, 738-743.
14. IARC. (2002) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene: World Health Organisation. IARC Press, Lyon, France.
15. Grosse, Y., Baan, R., Straif, K. et al. (2009) WHO International Agency for Research on cancer Monograph working group A review of human carcinogens-Part A: Pharmaceuticals. Lancet Oncol., 10, 13-14.
16. Schwetz, B. A. (2001) Safety of aristolochic acid. JAMA, 285, 2705-2726.
17. Jackson, L., Kofman, S., Weiss, A. and Brodovsky, H. (1964) Aristolochic acid (Nsc-50413): Phase I Clinical study. Cancer Chemother. Rep., 42, 35-37.
18. Mehes, J., Decsi, L., Varga, F. and Kovacs, S. (1958) [Selective chemical disconnection of the uriniferous tubes of the first order in rabbits]. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol., 234, 548-565.
19. Mengs, U. and Stotzem, C. D. (1993) Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch. Toxicol., 67, 307-311.
20. Zheng, F., Zhang, X. and Huang, Q. (2001) [Establishment of model of aristolochic acid-induced chronic renal interstitial fibrosis in rats]. Zhonghua Yi Xue Za Zhi, 81, 1095-1100.
21. Cosyns, J. P., Dehoux, J. P., Guiot, Y., Goebbels, R. M., Robert, A., Bernard, A. M. and van Ypersele de Strihou, C. (2001) Chronic aristolochic acid toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney Int., 59, 2164-2173.
22. Krumbiegel, G., Hallensleben, J., Mennicke, W. H., Rittmann, N. and Roth, H. J. (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica, 17, 981-991.
23. Schmeiser, H. H., Pool, B. L. and Wiessler, M. (1986) Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis, 7, 59-63.
24. Schmeiser, H. H., Bieler, C. A., Wiessler, M., van Ypersele de Strihou, C. and Cosyns, J. P. (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res., 56, 2025-2028.
25. Arlt, V. M., Alunni-Perret, V., Quatrehomme, G. et al. (2004) Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer, 111, 977-980.
26. Stiborova, M., Fernando, R. C., Schmeiser, H. H., Frei, E., Pfau, W. and Wiessler, M. (1994) Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32Ppostlabelling analysis using different chromatographic procedures. Carcinogenesis, 15, 1187-1192.
27. Mei, N., Arlt, V. M., Phillips, D. H., Heflich, R. H. and Chen, T. (2006) DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res., 602, 83-91.
28. Fernando, R. C., Schmeiser, H. H., Schert, H. and Wiessler, M. (1993) Formation and persistence of specific purine DNA adducts by 12Ppostlabelling in target and nontarget organs of rats treated with aristolochic acid I. In Phillips, D. H., Castegnaro, M. and Bartsch, H. (eds), Postlabeling Methods for Detection of DNA Adducts, Vol. 124. IARC, Lyon, France, pp. 167-171.
29. Lord, G. M., Cook, T., Arlt, V. M., Schmeiser, H. H., Williams, G. and Pusey, C. D. (2001) Urothelial malignant disease and Chinese herbal nephropathy. Lancet, 358, 1515-1516.
30. Broschard, T. H., Wiessler, M. and Schmeiser, H. H. (1995) Effect of sitespecifically located aristolochic acid DNA adducts on in vitro DNA synthesis by human DNA polymerase alpha. Cancer Lett., 98, 47-56.
31. Broschard, T. H., Wiessler, M., von der Lieth, C. W. and Schmeiser, H. H. (1994) Translesional synthesis on DNA templates containing sitespecifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis, 15, 2331-2340.
32. Schmeiser, H. H., Janssen, J. W. G., Lyons, J., Scherf, H. R., Pfau, W., Buchmann, A., Bartram, C. R. and Wiessler, M. (1990) Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res., 50, 5464-5469.
33. Schmeiser, H. H., Scherf, H. R. and Wiessler, M. (1991) Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett., 59, 139-143.
34. Chen, L., Mei, N., Yao, L. and Chen, T. (2006) Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol Lett., 165, 250-256.
35. Kohara, A., Suzuki, T., Honma, M., Ohwada, T. and Hayashi, M. (2002) Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (Muta(TM)Mouse). Mutat. Res., 515, 63-72.
36. Arlt, V. M., Wiessler, M. and Schmeiser, H. H. (2000) Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis, 21, 235-242.
37. Lord, G. M., Hollstein, M., Arlt, V. M., Roufosse, C., Pusey, C. D., Cook, T. and Schmeiser, H. H. (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis., 43, e11-e17.
38. Arlt, V. M., Schmeiser, H. H. and Pfeifer, G. P. (2001) Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis, 22, 133-140.
39. Liu, Z., Hergenhahn, M., Schmeiser, H. H., Wogan, G. N., Hong, A. and Hollstein, M. (2004) Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl Acad. Sci. USA, 101, 2963-2968.
40. Nedelko, T., Arlt, V. M., Phillips, D. H. and Hollstein, M. (2009) TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer, 124, 987-990.
41. Kucab, J. E., Phillips, D. H. and Arlt, V. M. (2010) Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J., 277, 2567-2583.
42. Rossiello, M. R., Laconi, E., Rao, P. M., Rajalakshmi, S. and Sarma, D. S. R. (1993) Induction of hepatic nodules in the rat by aristolochic acid. Cancer Lett., 71, 83-87.
43. Parsons, B. L., Myers, M. B.,Meng, F.,Wang, Y. and McKinzie, P. B. (2010) Oncomutations as biomarkers of cancer risk. Environ. Mol. Mutagen, 51, 836-850.
44. Meng, F., Knapp, G. W., Green, T., Ross, J. A. and Parsons, B. L. (2010) K-Ras mutant fraction in A/J mouse lung increases as a function of benzo(a)pyrene dose. Environ. Mol. Mutagen., 51, 146-155.
45. Verkler, T. L., Delongchamp, R. R., Miller, B. J., Webb, P. J., Howard, P. C. and Parsons, B. L. (2008) Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: A dose-response assessment. Mol. Carcinog., 47, 599-607.
46. Parsons, B. L., Beland, F. A., Von Tungeln, L. S., Delongchamp, R. R., Fu, P. P. and Heflich, R. H. (2005) Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol. Carcinog., 42, 193-201.
47. McKinzie, P. B. and Parsons, B. L. (2011) Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure. Environ. Mol. Mutagen, in press.
48. Parsons, B. L., Marchant-Miros, K. E., Delongchamp, R. R., Verkler, T. L., Patterson, T. A., McKinzie, P. B. and Kim, L. T. (2010) ACB-PCR quantification of K-ras codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest., 28, 364-375.
49. McKinzie, P. B., Delongchamp, R. R., Chen, T. and Parsons, B. L. (2006) ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue rats treated with N-hydroxy-2-acetylaminofluorene. Mutagenesis, 21, 391-397.
50. Chen, T., Mittelstaedt, R. A., Aidoo, A., Hamilton, L. P., Beland, F. A., Casciano, D. A. and Heflich, R. H. (2001) Comparison of hprt and lacI mutant frequency with DNA adduct formation in N-hydroxy-2-acetylaminofluorene-treated Big Blue rats. Environ. Mol. Mutagen., 37, 195-202.
51. Chen, T., Mittelstaedt, R. A., Shelton, S. D., Dass, S. B., Manjanatha, M. G., Casciano, D. A. and Heflich, R. H. (2001) Geneand tissue-specificity of mutation in Big Blue rats treated with the hepatocarcinogen N-hydroxy-2- acetylaminofluorene. Environ. Mol. Mutagen., 37, 203-214.
52. Roos, W. P. and Kaina, B. (2006) DNA damage-induced cell death by apoptosis. Trends Mol. Med., 12, 440-450.
53. Stiborova, M., Frei, E., Arlt, V. M. and Schmeiser, H. H. (2008) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res., 658, 55-67.
54. Gao, R., Zheng, F., Liu, Y., Zheng, D., Li, X. and Bo, Y. (2000) Aristolochic acid I-induced apoptosis in LLC-PK1 cells and amelioration of the apoptotic damage by calcium antagonist. Chin. Med. J. (Engl.), 113, 418-424.
55. Su, Z., Xu, S., Zheng, F. and Li, Y. (2002) [Aristolochic acid induced transdifferentiation and apoptosis in human tubular epithelial cells in vitro]. Zhonghua Yu Fang Yi Xue Za Zhi, 36, 301-304.
56. Balachandran, P., Wei, F., Lin, R. C., Khan, I. A. and Pasco, D. S. (2005) Structure activity relationships of aristolochic acid analogues: Toxicity in cultured renal epithelial cells. Kidney Int., 67, 1797-1805.
57. Simoes, M. L., Hockley, S. L., Schwerdtle, T., da Costa, G. G., Schmeiser, H. H., Phillips, D. H. and Arlt, V. M. (2008) Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol. Appl. Pharmacol., 232, 86-98.
58. Arlt, V. M., Zuo, J., Trenz, K., Roufosse, C. A., Lord, G. M., Nortier, J. L., Schmeiser, H. H., Hollstein, M. and Phillips, D. H. (2010) Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer, 128, 21-32.
59. Chen, T., Guo, L., Zhang, L., Shi, L., Fang, H., Sun, Y., Fuscoe, J. C. and Mei, N. (2006) Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinformatics, 7 (Suppl. 2), S20.
60. Guo, L., Lobenhofer, E. K., Wang, C. et al. (2006) Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol., 24, 1162-1169.
61. Stemmer, K., Ellinger-Ziegelbauer, H., Ahr, H. J. and Dietrich, D. R. (2007) Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res., 67, 4052-4068.
62. Stemmer, K., Ellinger-Ziegelbauer, H., Ahr, H. J. and Dietrich, D. R. (2009) Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors. Am. J. Pathol., 175, 1686-1698.